RxDoctor Payments Data

Warren Gentry, MD

Family Medicine · Clemson, SCNPI 1598825739

Payments from drug & device makers

$6,616in general payments, 2019–2025

Across 502 payments — averaging $13.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$851
  • AbbVie$833
  • AstraZeneca$562
  • Bayer$426
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$325
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$6,58299%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,616 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$141,352
Medicare patients
202
Services billed
1,930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$115,962
EliquisApixaban105$86,673
FarxigaDapagliflozin Propanediol66$47,892
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$42,684
MyrbetriqMirabegron43$28,315
MounjaroTirzepatide24$23,809
JardianceEmpagliflozin29$23,400
XareltoRivaroxaban29$23,383
RexultiBrexpiprazole15$22,441
TrintellixVortioxetine Hydrobromide28$18,867
KerendiaFinerenone24$16,516
Testosterone30$14,065
Tadalafil70$12,636
Rosuvastatin Calcium349$11,641
Diclofenac Sodium36$9,808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,156$115,962104 claims
PfizerEliquis$260$86,673105 claims
AstraZenecaFarxiga$562$47,89266 claims
GSKTrelegy Ellipta$229$42,68449 claims
Astellas Pharma US IncMyrbetriq$42$28,31543 claims
Lilly USA, LLCMounjaro$851$23,80924 claims
Boehringer IngelheimJardiance$79$23,40029 claims
Johnson & JohnsonXarelto$49$23,38329 claims
Otsuka America Pharmaceutical, Inc.Rexulti$103$22,44115 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$109$18,86728 claims
BayerKerendia$426$16,51624 claims
Esperion Therapeutics, Inc.Nexlizet$14$4,74412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Clemson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →